Soto HKA, Loza EO, García MN, Rodríguez GKG, Sánchez-Reyes L, Fanghänel SG

Idioma: Español
Referencias bibliográficas: 51
Paginas: 19-29
Archivo PDF: 219.68 Kb.

RESUMEN

El riesgo cardiovascular es responsable de un cuarto de las muertes por enfermedad coronaria, y dentro de estos pacientes el 75% son mayores de 65 años de edad, población a la que nos enfocaremos en esta revisión. Por ello es de suma importancia considerar tanto los beneficios clínicos como económicos de una terapia preventiva en este grupo poblacional. La prescripción en los ancianos se ha convertido en la actualidad en una cuestión compleja que tiende a incrementar el uso irracional de los fármacos, los errores de medicación, los efectos adversos, así como la subutilización o sobreutilización de los mismos. Las estatinas (inhibidores de la HMG-CoA reductasa), son consideradas como el tratamiento hipolipemiante de primera elección para la disminución del riesgo cardiovascular y a pesar de no haber publicaciones enfocadas en el uso exclusivo de estatinas en la población de adultos mayores así como de múltiples controversias, se pueden encontrar beneficios similares a los percibidos en poblaciones más jóvenes, pero con un enfoque en prevención primaria en la población de edad avanzada.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Partida Bush V. La transición demográfica y el proceso de envejecimiento en México. La Situación demográfica de México 2004. CONAPO. 2004:23-29.

2. Instituto Nacional de Estadística y Geografía. Mujeres y hombres en México 2010, 14ª edición. INEGI.

3. Instituto Nacional de Estadística y Geografía. Mujeres y hombres en México 2010, 14ª edición. INEGI.

4. Gómez Dantés O, Sesma S, Becerril V, Knaul F, Arreola H, Frenk J. Sistema de salud de México. Salud Pública de México. 2011;53 supl 2:S220-S232.

5. Breyne J, Juthier F, Corseaux D, et al. Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor–thrombin pathway and potential role through osteopontin alteration. Atherosclerosis. 2010;213(2):369-76.

6. Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potencials of statins?. Journal of Molecular and Cellular Cardiology. 2011;doi:10.1016/j.yjmcc. 2011.09.014.

7. Lasses y Ojeda LA, Torres Gutiérrez JL, Salazar E. Dislipidemia en el anciano. Archivos de Cardiología en México. 2004; 74(4):315-26.

8. Castilla Guerra L, Fernández Moreno MC, López Chozas JM, Jiménez Hernández MD. Statoms on stroke prevention: What an internist should know. European Journal of Internal Medicine. 2008;19:8-14.

9. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769e-81.

10. Cibickova L´ubica. Statins and their influence on brain cholesterol. Journal of Clinical Lipidology. 2011;Vol 5, Issue 5:373-9.

11. Freji A Gobal and Jawahar Mehta. Management of dyslipidemia in the elderly population. Therapeutic Advances in Cardiovascular Disease. 2010;4:375-83.

12. Martínez-Selles M, Datino T, Gómez Sánchez MA, Bañuelos C. Actualización en cardiología geriátrica. Rev Esp Cardiol. 2008;61(Supl 1):4-14.

13. Harley C, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson S. Low-Density Lipoprotein Cholesterol (LDL-C) Levels and LDL-C Goal Attainment Among Elderly Patients Treated with Rosuvastatin Compared with Other Statins in Routine Clinical Practice. Am J Geriatric Pharmacotherapy. 2007;5(3):185-94.

14. Kon Koh K, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis. 2011;215:1-8.

15. Lewis S. Lipid-lowering therapy: who can benefit?. Vascular Health and Risk Management. 2011;7:525-34.

16. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45-54.

17. Álvarez-Sala L, Valderrama M, Torres F, Agudo P, Gorostiza F, Millán J. Tratamiento hipolipemiante en ancianos. Rev Esp Geriatr Gerontol. 2001;36(4):195-209.

18. Blum A, Shamburek R. The pleiotropic effects of statins on endotelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203:325-30.

19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. The Lancet. 2002;360:7-22.

20. Ali R, Alexander K. Statins for the Primary Prevention of Cardiovascular Events in Older Adults: A Review of the Evidence. Am J of Geriatric Pharmacotherapy. 2007;5(1):52-63.

21. Desai H, Aronow WS, Ahn C, et al. Incidence of perioperative myocardial infarction 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins. Archives of Gerontology and Geriatrics. 2010;51:149-51.

22. Fruchart JC, Sacks F, Hermans MP, et. al. The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Dyslipidemic Patients. The American Journal of Cardiology. 2008;102 Supl 10):1K-34K.

23. Lardizabal J, Deedwania P. Lipid-Lowering Therapy with statins for the primary and secondary prevention of cardiovascular disease. Cardiol Clin. 2011;29:87-103.

24. Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol. 2009;19:530-5.

25. Macfarlane PW, Murray H, Sattar N, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace. 2011;13(5):634-63.

26. Rashidi A, Adler DS, Casscells M, Madjid M. Is it time to prescribe statins to patients with calcified aortic stenosis? American Heart Journal. 2005;150(1):41-5.

27. Meaney E, Vela A, Ramos A, Alemao E, Yin D. Cumplimiento de las metas con reductores del colesterol en pacientes mexicanos. El estudio COMETA México. Gac Méd Mex. 2004;140(5):493-501.

28. Martínez-Selles M, Datino T, Díaz-Castro O, López-Palop R. Actualización en cardiología geriátrica. Rev Esp Cardiol. 2010;63(Supl 1):17-28.

29. Latry P, Molimard M, Dedieu B, Couffinhal T, Bégaud B, Martin-Latry K. Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohorte study. BMC Cardiovascular Disorders. 2011;11:46.

30. Rinfret S, Babapulle MN, Costa V, et al. Class effects of statins in elderly patients with congestive heart failure: a population-based analisis. American Heart Journal. 2008;155(2): 316-23.

31. Ducharme N, Radhamma R. Hyperlipidemia in the Elderly. Clin Geriatr Med. 2008;24:471-87.

32. Allen Maycock CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Pearson RR, Li Q, Anderson JL; Intermountain Heart Collaborative Study. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol. 2002 Nov 20; 40(10):1777-85.

33. Nair AP, Darrow B. Lipid Magnagement in the Geriatric Patient. Endocrinol Metab Clin N Am. 2009;38:185-206.

34. Horwich T, MacLellan R, Fonarow G. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol. 2004;43: 642-8.

35. Illnait-Ferrer J. Estatinas, uso racional en el tratamiento de la dislipoproteinemia. Revista Cubana de Medicina General Integral. 2009;25(2):17-25.

36. Ko D, Mamdani M, Alter D. Lipid - Lowering therapy with Statins in High-Risk Elderly Patients, The Treatment-Risk Paradox. JAMA. 2004;291(15):1864-70.

37. Down JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Additional Perspectives on Tolerability of Long- Term Treatment With Lovastatin. American Journal Cardiology. 2001;87:1074-9.

38. Sales FM. The Role of High-Density Lipoprotein (HDL) Cholesterol in the Prevention and Treatment of Coronary Heart Disease: Expert Group Recommendations. The American Journal of Cardiology. 2001;90:134-45.

39. Shepherd J, Blauw GJ, Murphy MB, et al. The Design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Am J Cardiol. 1999;84:1192-7.

40. Shepherd J, Blauw GJ, Murphy MB, on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlledtrial. 2002;360(9346):1623-30.Affiliations

41. Afilal J, Duque G, Jukema JW, et al. Statins for Secondary Prevention in Elderly Patients. Journal of the American College of Cardiology. 2008;51(1):37-45.

42. Rashidi A, Wright JT. Drug Treatment of Hypertension in Older Hypertensives. Clinics in Geriatric Medicine. 2009;25(2):235-44.

43. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.

44. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129(9):681-9.

45. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19): 1349-57.

46. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7-22.

47. Aslam F, Haque A, Lee V, Foody J. Hyperlipidemia in Older Adults. Clin Geriatr Med. 2009;25:591-606.

48. Olsson AG, Schwartz GG, Szarek M, et al. Effects of highdose atorvastatin in patients > 65 years of age with acute coronary syndrome (from the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering [MIRACL] study). Am J Cardiol. 2007;99(5):632-5.

49. Ray KK, Bach RG, Cannon CP, et al. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006;27(19):2310-6.

50. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115(6):700-7.

51. Maycock CA. La terapia con estatinas también es beneficiosa en los pacientes ancianos con enfermedad cardiaca coronaria. Clin Invest Arterioscl. 2002;14(2):112-3.